SCHEMBL3322197

SCHEMBL3322197

CCC(CC)C(c1ccnn1-c1ccccc1)N(C)S(=O)(=O)c1ccc(C#N)cc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2C18 P33260 11/20 0.43
CYP2C9 P11712 10/20 0.43
CYP2C19 P33261 8/20 0.43
CYP2C8 P10632 11/20 0.43
C1R P00736 1/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
FPR1 P21462 1/20 0.37
CTSG P08311 1/20 0.36
CMA1 P23946 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323410 0.86 CYP2C18 (0.46) CYP2C18CYP2C9CYP2C19CYP2C8C1R
SCHEMBL3319766 0.82 CYP2C18 (0.41) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL27658539 0.79 CYP2C18 (0.46) CYP2C18CYP2C9CYP2C19CYP2C8FPR1
SCHEMBL3316928 0.78 EEF2K (0.43) CYP2C18CYP2C9CYP2C19CYP2C8POLB
SCHEMBL3319521 0.76 KMT2A (0.39) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL3320494 0.76 PSEN1 (0.42) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL3318883 0.74 CYP2C18 (0.35) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL27678450 0.69 CYP2C18 (0.40) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL27678446 0.69 CYP2C18 (0.40) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL11214876 0.66 NR4A3 (0.43) CYP2C18CYP2C9CYP2C19CYP2C8POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US claimed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP claimed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US claimed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US claimed
JP-2007517905-A 2007-07-05 JP claimed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP claimed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO claimed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US claimed
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP disclosed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 CYP2C18 1381/4885CYP2C9 726/4885CYP2C19 1431/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 CYP2C18 1381/4885CYP2C9 726/4885CYP2C19 1431/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 CYP2C18 1342/4885CYP2C9 487/4885CYP2C19 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.